Soysal,A.Gönüllü,E.Arslan,H.Kibar,B.S.Pop,S.Yurttaş,G.N.Adıgüzel,O.G.2024-05-252024-05-25202191344-630410.7883/yoken.JJID.2020.7812-s2.0-85107565471https://doi.org/10.7883/yoken.JJID.2020.781https://hdl.handle.net/20.500.14517/2554Little is known about the therapeutic use of hydroxychloroquine in pediatric patients with coronavirus disease 2019 (COVID-19). Here, we retrospectively retrieved data of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR-positive pediatric patients from 20 hospitals in 8 Turkish cities. We obtained epidemiological, clinical, and laboratory features of the patients, as well as the drugs used for treating COVID-19. A total of 237 nasopharyngeal swab SARS-CoV-2 PCR-positive children were included in the study from March 26, 2020 to June 20, 2020. The mean age of asymptomatic children (118 + 62 months) was higher than that of symptomatic children (89 + 69 months). Symptomatic children had significantly lower mean lymphocyte counts and higher mean CRP, D-dimer, procalcitonin, and LDH levels than asymptomatic children in the univariate analysis. Among 156 children, 78 (50%), 15, 44, and 21 were treated with a hydroxychloroquine-containing regimen, hydroxychloroquine + azithromycin + oseltamivir, hydroxychloroquine + azithromycin, and hydroxychloroquine alone, respectively. Among 156 patients who received medical treatment, 90 (58%) underwent pre- and/or post-treatment electrocardiogram (ECG). However, none of them had ECG abnormalities or required hydroxychloroquine discontinuation due to adverse drug reactions. © 2021, National Institute of Health. All rights reserved.eninfo:eu-repo/semantics/openAccess[No Keyword Available]ArticleQ4Q3744273279PubMed:33250495